Volume | 10,394 |
|
|||||
News | - | ||||||
Day High | 0.76 | Low High |
|||||
Day Low | 0.701101 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Phio Pharmaceuticals Corporation | PHIO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.721 | 0.701101 | 0.76 | 0.7105 | 0.73 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
122 | 10,394 | US$ 0.7325152 | US$ 7,614 | - | 0.50 - 3.3899 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
16:11:46 | 20 | US$ 0.7301 | USD |
Phio Pharmaceuticals Corporation Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.73M | 2.44M | - | 0 | -10.83M | -4.43 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Phio Pharmaceuticals News
Date | Time | Source | News Article |
---|---|---|---|
5/28/2024 | 16:00 | Edgar (US Regulatory) | Form 8-K - Current report |
5/20/2024 | 16:03 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of.. |
5/20/2024 | 15:59 | Edgar (US Regulatory) | Form RW - Registration Withdrawal Request |
5/17/2024 | 15:45 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of.. |
5/17/2024 | 08:04 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] |
5/17/2024 | 08:00 | GlobeNewswire Inc. | Phio Pharmaceuticals Secures New Investor |
5/17/2024 | 08:00 | Edgar (US Regulatory) | Form 8-K - Current report |
5/16/2024 | 07:00 | GlobeNewswire Inc. | Phio Pharmaceuticals Presents This Week at the Society for.. |
5/15/2024 | 12:00 | GlobeNewswire Inc. | Phio Pharmaceuticals Announces Completion of Dosing in First.. |
5/09/2024 | 16:25 | GlobeNewswire Inc. | Phio Pharmaceuticals Reports Q1 2024 Results and Provides.. |
5/09/2024 | 16:23 | Edgar (US Regulatory) | Form 8-K - Current report |
5/09/2024 | 16:20 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PHIO Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.74 | 0.78 | 0.68 | 0.731896 | 22,275 | -0.0295 | -3.99% |
1 Month | 0.82 | 0.8401 | 0.68 | 0.7696818 | 51,732 | -0.1095 | -13.35% |
3 Months | 0.81 | 1.05 | 0.604849 | 0.7918569 | 222,530 | -0.0995 | -12.28% |
6 Months | 0.7158 | 1.15 | 0.50 | 0.8209875 | 268,302 | -0.0053 | -0.74% |
1 Year | 3.09 | 3.3899 | 0.50 | 1.81 | 520,997 | -2.38 | -77.01% |
3 Years | 27.84 | 29.64 | 0.50 | 14.38 | 663,606 | -27.13 | -97.45% |
5 Years | 4.68 | 130.20 | 0.50 | 19.11 | 722,493 | -3.97 | -84.82% |
Phio Pharmaceuticals Description
Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The company's pipeline products include PH-762, PH-804, PH-790, and others. |